SCHEMBL3950722

SCHEMBL3950722

CC(C)(C)NS(=O)(=O)c1cc(C(=O)O)ccc1Br

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.64
ERAP1 Q9NZ08 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 1/20 0.44
PKM P14618 2/20 0.44
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
PTGES O14684 1/20 0.43
ALOX5 P09917 1/20 0.43
CDC25B P30305 1/20 0.42
FABP4 P15090 1/20 0.42
FABP5 Q01469 1/20 0.42
POLB P06746 3/20 0.42
HSD17B10 Q99714 1/20 0.42
PTK2B Q14289 1/20 0.41
KDM4E B2RXH2 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22409253 0.86 SMN1; SMN2 (0.51) HTTMEN1KMT2AALDH1A1MAPT
SCHEMBL979667 0.85 NOTUM (0.49) HTTMEN1KMT2AALDH1A1PKM
SCHEMBL13543503 0.84 HTT (0.68) HTTERAP1MEN1KMT2AALDH1A1
SCHEMBL13794381 0.83 POLB (0.47) HTTMEN1KMT2APKMNPSR1
SCHEMBL6153148 0.83 NPSR1 (0.44) HTTKMT2APKMNPSR1MAPT
SCHEMBL8067664 0.82 HTT (0.69) HTTERAP1MEN1KMT2AALDH1A1
SCHEMBL11595561 0.81 POLB (0.62) HTTMEN1KMT2AALDH1A1MAPT
SCHEMBL26144894 0.81 PTK2B (0.62) HTTPKMNPSR1MAPTTP53
SCHEMBL3950862 0.81 CDC25B (0.63) HTTALDH1A1PKMNPSR1MAPT
SCHEMBL13543506 0.81 NPSR1 (0.65) HTTERAP1MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360120-A1 RAD51 INHIBITORS CYTEIR THERAPEUTICS, INC. 2024-10-31 US disclosed
EP-3938358-B1 RAD51 INHIBITORS CYTEIR THERAPEUTICS INC (US) 2024-10-02 EP disclosed
CN-114072390-B RAD51 inhibitors 赛泰尔治疗公司 2024-06-11 CN disclosed
US-11932636-B2 RAD51 inhibitors CYTEIR THERAPEUTICS, INC. (US) 2024-03-19 US disclosed
US-20220259198-A1 RAD51 INHIBITORS CYTEIR THERAPEUTICS, INC. 2022-08-18 US disclosed
CN-114072390-A RAD51 inhibitors 赛泰尔治疗公司 2022-02-18 CN disclosed
US-11247988-B2 RAD51 inhibitors CYTEIR THERAPEUTICS, INC. (US) 2022-02-15 US disclosed
US-20200291014-A1 RAD51 INHIBITORS CYTEIR THERAPEUTICS, INC. 2020-09-17 US disclosed
WO-2020186006-A1 RAD51 INHIBITORS CYTEIR THERAPEUTICS, INC. (US) 2020-09-17 WO disclosed
US-7544676-B2 Sulfamoyl benzamides and methods of their use ADOLOR CORPORATION (US) 2009-06-09 US disclosed
US-7544676-B2 Sulfamoyl benzamides and methods of their use ADOLOR CORPORATION (US) 2009-06-09 US disclosed
US-7544676-B2 Sulfamoyl benzamides and methods of their use ADOLOR CORPORATION (US) 2009-06-09 US disclosed
US-20080058302-A1 Sulfamoyl Benzamides and Methods of Their Use CALIXA THERAPEUTICS, INC. 2008-03-06 US disclosed
US-20080058302-A1 Sulfamoyl Benzamides and Methods of Their Use CALIXA THERAPEUTICS, INC. 2008-03-06 US disclosed
US-20080058302-A1 Sulfamoyl Benzamides and Methods of Their Use CALIXA THERAPEUTICS, INC. 2008-03-06 US disclosed
WO-2007058960-A1 SULFAMOYL BENZAMIDES AS CANNABINOID RECEPTOR MODULATORS ADOLOR CORPORATION (US) 2007-05-24 WO disclosed
WO-2007058960-A1 SULFAMOYL BENZAMIDES AS CANNABINOID RECEPTOR MODULATORS ADOLOR CORPORATION (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11247988-B2 RAD51 inhibitors RAD51, MRE11, RAD54L HTT 319/4885ERAP1 3439/4885MEN1 791/4885
US-20220259198-A1 RAD51 INHIBITORS RAD51, MRE11, RAD54L HTT 319/4885ERAP1 3439/4885MEN1 791/4885
US-20080058302-A1 Sulfamoyl Benzamides and Methods of Their Use CNR2, TRPV1, CNR1 HTT 1587/4885ERAP1 3483/4885MEN1 3250/4885
US-20200291014-A1 RAD51 INHIBITORS RAD51, MRE11, RAD54L HTT 319/4885ERAP1 3439/4885MEN1 791/4885
US-20240360120-A1 RAD51 INHIBITORS RAD51, MRE11, RAD54L HTT 319/4885ERAP1 3439/4885MEN1 791/4885
US-11932636-B2 RAD51 inhibitors RAD51, MRE11, RAD54L HTT 319/4885ERAP1 3439/4885MEN1 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.